The oligonucleotide nanostructures enable pattern-recognized targeting of diseases, particularly useful as high-specificity detectors and inhibitors of viruses and toxins, such as for Dengue virus particles. The nanostructures include an oligonucleotide scaffold with a plurality of binders arranged in a pattern conforming to a plurality of surface epitopes of a target disease. Binding of the scaffolds to these surface epitopes has been shown to have inhibitory effects against the target disease. The scaffolds can also include functional domains that activate upon target binding. Assembly of the scaffolds can be achieved via annealing of separate oligonucleotide segments of predetermined length and sequence, which also advantageously define locations of binding domains in the resulting structure. This approach provides precise control over the spacing and orientation of epitope binding sites in the scaffold.

Provided are compositions and methods useful to the determination of whether a microbial contaminant is present in a biological therapeutic production process. Specifically, an artificial positive amplification control plasmid and unique quantitative PCR detection probe are provided, which enables the rapid and real-time detection of a false positive result.

Disclosed is a method for detecting virus particles in a sample, comprising the steps of: (a) incubating the sample with at least one virus-binding molecule bound to a solid phase; and (b) detecting binding of virus particles to the at least one virus-binding molecule bound to the solid phase. Also disclosed is a kit for use in this method.

The present disclosure generally relates to systems and methods for detecting viruses, e.g., using microfluidic devices. Certain embodiments are generally directed to systems and methods that are able to detect pathogens such as viruses or bacteria by encapsulating a sample in droplets, and applying amplification reagents to the droplets able to amplify nucleic acids therein, e.g., using loop mediated isothermal amplification (LAMP) or other amplification techniques. In addition, some aspects are generally directed to identifying a species in a sample, e.g., at very low concentrations. In some cases, the sample may be broken into droplets, arid the droplets determined to determine the species.

Systems and methods for determining the presence or absence of an analyte including a nucleic acid (e.g., DNA and RNA), a small molecule (e.g., proteins and amino acid chains), and one or more electrolytes (e.g., Na.sup.+ and K.sup.+). The system or method may detect multiple analytes (e.g., a first DNA and a second DNA) and/or multiple types of analytes (e.g., an RNA and an antibody protein). The signal readout provided by the system or method may be readily understood and may be correlated with a health condition (e.g., hydration or exposure to an infectious agent). The system may be wearable and may analyze one or more biofluids.

Provided herein are methods and compositions for rapid, highly sensitive detection of SARS-CoV-2 in biological samples. In particular, provided herein is a rapid, low-cost method for detecting SARS-CoV-2 that provides reliable, visible test results and does not require PCR reagents, elaborate biosafety precautions, or sophisticated laboratory equipment.

Provided are methods of making a SARS-CoV-2 (COVID-19) infection classifier for a platform, and optionally a non-COVID-19 viral infection classifier, a bacterial infection classifier, a non-infectious illness classifier, and/or a healthy subjects classifier for the platform. Methods and systems for determining the presence of SARS-CoV-2 (COVID-19) infection in a subject or for determining the viral stage of infection of a SARS-CoV-2 (COVID-19) illness in a subject suffering therefrom are also provided.

Provided are methods of making a SARS-CoV-2 (COVID-19) infection classifier for a platform, and optionally a non-COVID-19 viral infection classifier, a bacterial infection classifier, a non-infectious illness classifier, and/or a healthy subjects classifier for the platform. Methods and systems for determining the presence of SARS-CoV-2 (COVID-19) infection in a subject or for determining the viral stage of infection of a SARS-CoV-2 (COVID-19) illness in a subject suffering therefrom are also provided.

Integrated diagnostic devices comprising peptide-DNA conjugates for analyte detection, an embedded biomolecular computing system for sample analysis, and a layered device architecture are provided herein. In particular, provided herein are devices comprising a layered architecture that enables diagnostic reagents, sample components, and reaction products to flow through the system with minimal user intervention.

The present invention provides a rapid viral nucleic acid detection kit prepared by using a novel RecA enzyme and the detection method thereof. By editing the recombinase RecA gene, the expressed RecA protein has better solubility and recombinase activity. The RecA protein is used to prepare recombinase dry powder, further the formula of the recombinase dry powder and the ratio are optimized; and specific primers for the ASFV p72 gene are designed for the rapid nucleic acid detection of ASFV, significantly improving the detection sensitivity. In addition, the detection time is short, which effectively avoids missed detection and false detection, and helps prevention of epidemic.